No articles found for this sector...

================================================================================

No articles found for this sector...

================================================================================

[TITLE]Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference:
[TEXT]
ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 4:00 p.m. ET at the Lotte New York Palace in New York City.

Investors interested in arranging a meeting with company management during the conference should contact the Piper Sandler conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section of the Supernus Pharmaceuticals website at www.supernus.com . An archived replay of the webcasts will be available for 60 days on the Company's website following the conference.
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3193017/19871/en/Supernus-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html


[TITLE]BK Virus Infection Market Trends, Strategies and Business Prospects 2025-2035 - Lack of FDA-Approved Drugs Spurs Innovation in BK Virus Treatment:
[TEXT]
Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "BK Virus Infection Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.

The key drivers propelling the BK virus infection drug market stem largely from the growing immunocompromised patient population. Organ transplantation, particularly kidney transplants, is increasing globally. For instance, the United Network for Organ Sharing (UNOS) reported over 23,000 kidney transplants in the US alone in 2023, a population highly vulnerable to BKV reactivation. This surge directly increases the demand for effective management of BKV infections.

Furthermore, awareness of BKV-related complications among nephrologists and transplant surgeons has risen, leading to routine BKV screening post-transplant, which further stimulates the market for therapeutic drugs. Off-label use of antivirals such as cidofovir and leflunomide remains prevalent despite their nephrotoxicity and limited efficacy, underscoring the urgent need for targeted drug development. Additionally, widespread immunosuppressive regimens, essential to prevent graft rejection, inadvertently increase susceptibility to BKV reactivation, making antiviral treatment options a critical unmet need.

Despite growing awareness and demand, several challenges constrain the BK virus infection drug market. Foremost is the absence of FDA-approved antiviral agents specifically targeting BKV, which forces clinicians to rely on off-label medications. Both drugs, while somewhat effective, are associated with significant side effects; for example, nephrotoxicity can exacerbate kidney damage, a grave concern for transplant patients.

Managing the delicate balance between reducing immunosuppression to control the virus and maintaining sufficient immunosuppression to prevent graft rejection adds complexity to treatment protocols, making standardized drug regimens elusive. Financial barriers also exist high costs associated with frequent viral load monitoring and long-term therapy can restrict access, especially in resource-limited settings such as parts of Southeast Asia and Africa, where transplant infrastructure is growing but limited.

However, the BK virus infection market holds several promising opportunities for innovation and growth. Drug developers are increasingly focusing on creating targeted antiviral agents that inhibit specific stages of BKV replication, potentially improving efficacy while minimizing side effects. For example, AlloVir is advancing adoptive T-cell therapies that harness the patient's immune cells to specifically attack BKV-infected cells a personalized treatment approach showing encouraging early clinical results. This form of immunotherapy could revolutionize BKV management, reducing dependence on toxic antivirals.

Additionally, integrating companion diagnostics with therapeutic regimens presents an opportunity for precision medicine; real-time viral load tracking via sensitive PCR assays allows clinicians to tailor therapy intensity, improving patient outcomes. Combination therapies that pair antivirals with immune modulators are also under exploration, aiming to simultaneously suppress viral replication and optimize immune response. Market expansion in emerging economies is noteworthy. This expanding transplant ecosystem, combined with increasing healthcare investments, creates fertile ground for introducing novel BKV therapies.

Moreover, market trends reflect broader shifts in medical innovation and healthcare delivery. Precision medicine is becoming central to BKV management, with clinicians tailoring treatment based on viral load measurements and patient-specific immune profiles. For example, many transplant centers in the U.S. and Europe have adopted routine BKV viral load monitoring protocols to guide immunosuppressant adjustments and antiviral use, minimizing overtreatment.

Investment in immunotherapies like adoptive T-cell therapy is growing, reflecting confidence in cell-based approaches to control persistent viral infections. The use of biomarkers and molecular diagnostics is influencing not only clinical practice but also drug development pipelines, with pharmaceutical companies increasingly developing integrated solutions that combine diagnostics with therapeutics. Collaborations between biotech firms and leading transplant centers, such as the partnership between AlloVir and academic institutions, accelerate clinical trials and validation.

The current therapeutic landscape is dominated by off-label use of antivirals like cidofovir and leflunomide. Despite their limitations, these drugs remain the mainstay of BKV treatment due to the absence of approved alternatives. For example, a multicenter study in Europe highlighted the cautious use of leflunomide to reduce viral load but also noted significant side effects limiting broader adoption.

Emerging players such as AlloVir are shifting the paradigm by developing adoptive T-cell therapies that target BKV with high specificity, positioning themselves as leaders in immunotherapeutic innovation. Large pharmaceutical companies are also exploring antiviral candidates with activity against polyomaviruses, seeking to fill the gap in approved treatments.

Market Dynamics:

Drivers Increasing incidences of BK virus infections among organ transplant recipients. Rising awareness and advancements in diagnostic technologies. Growing demand for effective antiviral drugs.

Challenges Lack of effective treatment options currently available in the market. High costs associated with the development of new therapeutics.

Case Studies Implementation of new diagnostic standards in the U.S. hospitals.

Industry Trends Focus on personalized medicine and targeted therapies for BK virus infections.

Opportunities Expansion of research and development for novel therapeutic solutions. Potential market growth in emerging economies due to rising healthcare infrastructure.

Company Profiles:

Kalaris Therapeutics (AlloVir)

Hybridize Therapeutics

Orthogon Therapeutics

Vera Therapeutics, Inc.

AiCuris

Memo Therapeutics AG

SymBio Pharmaceuticals Limited
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192888/28124/en/BK-Virus-Infection-Market-Trends-Strategies-and-Business-Prospects-2025-2035-Lack-of-FDA-Approved-Drugs-Spurs-Innovation-in-BK-Virus-Treatment.html


[TITLE]Alcoholic Hepatitis Market Analysis and Forecast, 2025-2035 - Innovative Therapies, TNF Inhibitors and Stem Cell Treatments, are on the Horizon:
[TEXT]
Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "Alcoholic Hepatitis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.

The global alcoholic hepatitis market is primarily driven by the increasing prevalence of global alcohol consumption, rising alcohol-related liver diseases, and increased public awareness of liver health. Advancements in diagnostic methods and early screening programs have improved the identification and management of this condition, prompting a growing demand for more effective therapies.

Current treatment strategies primarily include corticosteroids and nutritional support; however, research is advancing toward the development of novel anti-inflammatory agents, biologics, and targeted molecular therapies. Emerging approaches such as TNF inhibitors and stem cell therapies are also being explored, offering new virtues to improve patient outcomes.

However, the market does face challenges such as the absence of disease-specific treatments, which restricts therapeutic options and leads to variability in clinical outcomes. Moreover, social stigma and underdiagnosis of alcohol use disorders can delay patient access to care.

On the other hand, growth opportunities are emerging from expanding access to treatment in developing countries, where healthcare infrastructure is improving and public health initiatives are addressing alcohol-related harm. Further, pharmaceutical companies are actively investing in research and development to address unmet needs and improve therapeutic outcomes, which is expected to drive innovation and long-term growth in the alcoholic hepatitis market landscape.

Industrial Impact

Technological advancements in drug development, diagnostics, and patient monitoring solutions are driving progress in the alcoholic hepatitis market. Emerging therapies and non-invasive diagnostic tools are improving early detection, treatment outcomes, and long-term disease management, especially in severe cases.

Demand Drivers for the Global Alcoholic Hepatitis Market:

Increasing global incidence of alcohol-related liver diseases, particularly in regions with high alcohol consumption

Heightened public awareness of liver health and expanded screening initiatives promote earlier medical engagement

High relapse and readmission rates necessitate long-term disease management, creating sustained demand for pharmacological and supportive care

Limitations for the Global Alcoholic Hepatitis Market:

Limited access to liver specialists and advanced treatment options in emerging markets

Stigma associated with alcohol-related diseases can lead to underdiagnosis and poor treatment adherence, thereby hindering the market growth.

How can this report add value to an organization?

Product/Innovation: This report provides comprehensive insights into the current trends in alcoholic hepatitis, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from alcoholic hepatitis, improving outcomes and enhancing market penetration.

Competitive: A detailed competitive landscape analysis helps organizations benchmark their market standing against key players such as Aldeyra Therapeutics and Intercept Pharmaceuticals. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global alcoholic hepatitis market.

Key Market Players and Competition Synopsis

The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global alcoholic hepatitis market. Leading players in the global alcoholic hepatitis market include:

Aldeyra Therapeutics

Intercept Pharmaceuticals, Inc.

DURECT Corporation

Market Dynamics:

Drivers: The increasing prevalence of alcoholic hepatitis globally. Advancements in treatment options and medical research. Rising awareness and early diagnosis campaigns.

Challenges: Lack of effective therapeutic options. High cost of treatment and healthcare services. Social stigma and lack of awareness.

Case Studies: Successful intervention programs in North America. Community health initiatives in Europe.

Industry Trends: Growing partnerships and collaborations in the healthcare sector. Increased investment in R&D for alcoholic hepatitis.

Opportunities: Development of innovative therapies and drugs. Expansion into emerging markets.

Company Profiles:

Aldeyra Therapeutics, Inc. Company Overview Product Portfolio Target Customers/End Users Analyst View

Alfasigma Group (Intercept Pharmaceuticals, Inc.) Company Overview Product Portfolio Target Customers/End Users Analyst View

DURECT Corporation Company Overview Product Portfolio Target Customers/End Users Analyst View
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192883/28124/en/Alcoholic-Hepatitis-Market-Analysis-and-Forecast-2025-2035-Innovative-Therapies-TNF-Inhibitors-and-Stem-Cell-Treatments-are-on-the-Horizon.html


[TITLE]Digital Transformation in Healthcare Market Size to Reach USD 258.22 Billion by 2033 Driven by Technology Adoption and Patient Centric Care – SNS Insider:
[TEXT]
Austin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- According to S&S Insider, the global Digital Transformation in Healthcare
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192874/0/en/Digital-Transformation-in-Healthcare-Market-Size-to-Reach-USD-258-22-Billion-by-2033-Driven-by-Technology-Adoption-and-Patient-Centric-Care-SNS-Insider.html


===== Company info for companies mentioned in news =====

Company name: alcoholic hepatitis
name: alcoholic hepatitis
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: bk virus
name: bk virus
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: digital transformation
name: digital transformation
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=digital+transformation&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: supernus pharmaceuticals
name: supernus pharmaceuticals
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=supernus+pharmaceuticals&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

================================================================================

[TITLE]Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients:
[TEXT]
-- Tablet PK exposure increases proportionally with an increase in dose --

-- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced variability --

-- Tablet steady state showing Cmax/Cmin ratio <2 --

MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced positive tablet PK data from ongoing Phase 1/1b open-label study evaluating PAS-004 in adult patients with neurofibromatosis type 1 (NF1) with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas ( NCT06961565 ).

Pharmacokinetics (PK)

PAS-004 has demonstrated in the tablet formulation (4mg and 8mg cohorts):

Linear PK and dose-proportionality

and PK curve with Cmax/Cmin ratio <2 , with Cmax and Cmin above the IC50 (half-maximal inhibitory concentration) from our cellular assay

, with Cmax and Cmin above the IC50 (half-maximal inhibitory concentration) from our cellular assay Long half-life (~57 hours)

Cohort 1 (4mg tablet) has demonstrated:

AUC : 1,120 ng·h/mL

Cmax : 58.1 ng/mL

Cmin : 37.6 ng/mL

Cohort 2 (8mg tablet) has demonstrated:

AUC : 2,290 ng·h/mL

Cmax : 118 ng/mL

Cmin : 75.4 ng/mL

Dose normalized exposures following once daily administration of PAS-004 tablets were approximately 3-fold higher than those following administration with the capsule formulation, resulting in the 8mg tablet area under the curve (AUC) and Cmax being slightly greater than those of the 22mg capsule. The tablet formulation has demonstrated less patient variability and a similar Tmax range when compared to the capsule formulation. This is consistent with the pre-clinical evaluation of the two formulations in the dog toxicology studies.

Graph 1 below represents the tablet PK curve at steady state for the 4mg and 8mg doses and Graph 2 below represents the 8mg tablet PK curve at steady state as compared to 22mg capsule dose at steady state from our ongoing Phase 1 trial in advanced cancer patients:

Graph 1:

Graph 2:
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192937/0/en/Pasithea-Therapeutics-Announces-Positive-PAS-004-Tablet-Pharmacokinetic-PK-Data-in-Ongoing-Phase-1-1b-Trial-in-Adult-NF1-Patients.html


[TITLE]Oncology Biomarker Market Accelerates Toward USD 113.5 Billion by 2034:
[TEXT]
Ottawa, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The global oncology biomarker
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192889/0/en/Oncology-Biomarker-Market-Accelerates-Toward-USD-113-5-Billion-by-2034.html


[TITLE]Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | According to DataM Intelligence:
[TEXT]
AUSTIN, Texas and TOKYO, Nov. 21, 2025 /PRNewswire/ -- According to DataM Intelligence, the Prostate Cancer Drugs
[Source link]: https://www.prnewswire.co.uk/news-releases/prostate-cancer-drugs-market-to-reach-usd-28-10-billion-by-2033--according-to-datam-intelligence-302623116.html


[TITLE]Biotechnology CMO and CDMO Market on Track for USD 199.67 Billion by 2034 with a Strong 11.54% CAGR:
[TEXT]
Ottawa, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The global biotechnology CMO and CDMO
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192861/0/en/Biotechnology-CMO-and-CDMO-Market-on-Track-for-USD-199-67-Billion-by-2034-with-a-Strong-11-54-CAGR.html


===== Company info for companies mentioned in news =====

Company name: bioatla
symbol: BCAB
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763946761
name: bioatla
------------------------------------------------------------------

Company name: datam intelligence
name: datam intelligence
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: novabridge biosciences
symbol: 0VY.F
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763946762
name: novabridge biosciences
------------------------------------------------------------------

Company name: pasithea therapeutics
name: pasithea therapeutics
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=pasithea+therapeutics&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

================================================================================

No articles found for this sector...

================================================================================

